Monica Stonehill

Healio spoke with Marlyn Mayo, MD, about increased research focused on symptoms of primary sclerosing cholangitis presented at The Liver Meeting, as well as treatments being investigated.“Traditionally, we haven’t paid a lot of attention to symptoms in PSC, except when patients have acute cholangitis,” Mayo, professor of internal medicine at UT Southwestern Medical Center, said.

In this video, Marlyn Mayo, MD, discusses data from a real-world case series investigating the efficacy and safety of maralixibat in eight patients with primary sclerosing cholangitis.“What they found was impressive — almost complete resolution of pruritus in the patients,” Mayo, professor of internal medicine at UT Southwestern Medical Center, told Healio.

Linerixibat decreased serum interleukin-31 levels in patients with primary biliary in cholangitis after 24 weeks, which may be linked to an improvement in pruritus and response to treatment, according to data presented at The Liver Meeting.“Interleukin-31 (IL-31) has been identified as a potential pruritogen in cholestatic pruritus,” Christopher Bowlus, MD, chief of gastroenterology

PHOENIX — In this video, Paul Kwo, MD, discusses preliminary results from the phase 3 MAESTRO-NAFLD-1 trial assessing resmetirom in patients with compensated metabolic dysfunction-associated steatohepatitis cirrhosis.“There’s a larger effort ongoing, but this initial glimpse suggests that there may be benefit to resmetirom in patients with cirrhosis, in addition to its known

PHOENIX — Use of rifaximin soluble solid dispersion tablets for up to 24 weeks did not increase infection-related adverse events among patients with cirrhosis, according to data presented at ACG Annual Scientific Meeting.Findings also showed no antibiotic-resistant infections associated with its use.

PHOENIX — In this video, Mazen Noureddin, MD, MHSc, professor of medicine at Houston Methodist, highlights current treatments and others in the pipeline for metabolic dysfunction-associated steatohepatitis.Two medications are currently approved for MASH with fibrosis: Rezdiffra (resmetirom, Madrigal Pharmaceuticals), an oral thyroid hormone receptor-beta selective agonist, and Wegovy

PHOENIX — In this video, Medora D. Rodrigues, MD, MPH, discusses results of retrospective cohort study that showed tirzepatide was linked to a lower risk for biliary disease compared with semaglutide.“For patients who have been treated with semaglutide and tirzepatide for diabetes and weight loss management, clinicians can make a better decision between these two medications,

Currently, more than 300 million people are diagnosed with hepatitis around the world, according to the World Hepatitis Alliance. Cases continue to rise, with more than 2 million new cases each year. Among the five hepatitis viruses, HBV, HCV and HDV usually cause chronic disease, liver cancer and cirrhosis, whereas HAV and HEV cause acute disease but may lead to more serious complications in

Physiological metrics captured via wearable devices may help identify and predict flares in inflammatory bowel disease, Robert P. Hirten, MD, told Healio, and could potentially play a role in remote monitoring of disease activity. “As gastroenterologists, one of the things that we find is that between office visits, there sometimes can be relatively little contact or interaction between

Approximately 14% of the U.S. population lives in rural areas, where access to health care may be limited by insurance coverage, geography and infrastructure, and provider shortages, according to HHS. Known as “medical deserts,” these areas can lead to higher morbidity and mortality as well as adverse effects on health services.

A 2016 report from the Health Resources and Services Administration National Center for Health Workforce Analysis projected a shortage of 1,630 full-time physicians by 2025 in the field of gastroenterology.However, that is not where the shortage ends. According to Karmen Blackwell, a Health Resources and Services Administration (HRSA) spokesperson, “In 2037, there will be a projected

SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through 104 weeks, according to VIVID-2 study results. “The durability of response and remission among patients who were in endoscopic response at week 52 of the initial study is a critical result

There are approximately 100,000 alcohol-related cancer cases annually in the U.S. and 20,000 deaths due to alcohol-related cancer, according to an HHS press release.This is one of the many tipping points that sparked U.S. Surgeon General Vivek Murthy, MD, MBA, to issue an advisory designed to raise awareness about alcohol consumption and reduce the incidence of alcohol-related cancers and deaths.

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the U.S. by 2050, which could be minimized by effective preventive and management strategies, researchers wrote. “People with MASLD or [metabolic dysfunction–associated steatohepatitis] are at increased risk of adverse liver-related health outcomes, and MASH is

Dry January has become an increasingly popular trend in which people abstain from alcohol use for 1 month to reset their health after the holiday season. But, for some, it could be a wake-up call about their struggles with alcohol.In 2024, 35% of Americans aged 21 to 24 years reported completing Dry January, which was markedly higher than the 14% of Americans aged 55 years or older, according to

From 2002 to 2021, the incidence rate of alcohol-associated hepatitis “more than doubled” among adolescents and young adults in Ontario, Canada, with the highest uptick observed among females, according to research in JAMA Network Open. “Liver-related harms from alcohol are increasing at alarming rates among adolescents and young adults, especially among females, and targeted

Individuals with negative colonoscopy screening results had lower long-term risk for colorectal cancer and related mortality, with researchers suggesting the recommended 10-year rescreening interval may be extended for this population. “Among average-risk individuals undergoing colonoscopy screening, most have negative examination findings and are free of any neoplasia,” Markus Dines

Prucalopride was safe and effective in increasing the frequency of complete spontaneous bowel movements in patients with chronic idiopathic constipation, regardless of age, BMI or renal function, according to data. “Prucalopride (1 or 2 mg once daily) has been demonstrated to improve the number of complete spontaneous bowel movements in patients with CIC over a 12-week treatment period as

Hispanic patients hospitalized for alcohol use disorder were more likely to develop alcohol-associated hepatitis, decompensated cirrhosis and related complications compared with non-Hispanic white patients, according to published data. “Alcohol use disorder (AUD), a major contributor to alcohol-associated liver disease (ALD), has been increasing in the United States,” Soo Young Hwang,

Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as effective as colonoscopy.In July, the FDA approved Guardant Health’s Shield, the first blood test approved as a primary CRC screening option. It joins the pipeline of noninvasive screening